NCT00298688已完成2 期
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 56
- 试验地点
- 3
- 主要终点
- To determine the disease control rate in these patients
研究概览
简要总结
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent
- •Histologically confirmed, relapsed or refractory SCLCr
- •Aged 18 or over and a life expectancy of more than 2 months
排除标准
- •Any evidence of clinically active interstitial lung disease
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
结局指标
主要结局
To determine the disease control rate in these patients
次要结局
- To determine the objective response rate at trail closure in these patients
- To determine the time to progression-or-death in these patients
- To determine overall survival in these patients
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00173875National Taiwan University Hospital108
终止
3 期
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLCNon Small Cell Lung CarcinomaNCT00234468AstraZeneca490
已完成
2 期
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and NeckHead and Neck NeoplasmsNCT00519077University of Chicago44
已完成
2 期
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaMyelogenous Leukemia, AcuteNCT00130702Dana-Farber Cancer Institute18
已完成
2 期
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck CarcinomaHead and Neck CancerNCT00228488AstraZeneca60